Cocrystal Pharma (COCP) to Release Quarterly Earnings on Thursday

Cocrystal Pharma (NASDAQ:COCP) is anticipated to announce its results before the market opens on Thursday, August 13th. Analysts expect the company to post earnings of ($0.17) per share and revenue of $0.2250 million for the quarter.

Cocrystal Pharma (NASDAQ:COCP) last released its earnings results on Friday, May 15th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02). The business had revenue of $0.23 million for the quarter, compared to the consensus estimate of $0.23 million. On average, analysts expect Cocrystal Pharma to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Cocrystal Pharma Stock Up 1.9%

Shares of NASDAQ:COCP opened at $1.08 on Tuesday. The firm has a fifty day moving average of $0.99 and a two-hundred day moving average of $1.10. The firm has a market capitalization of $14.89 million, a P/E ratio of -1.48 and a beta of 1.43. Cocrystal Pharma has a 12-month low of $0.76 and a 12-month high of $2.67.

Hedge Funds Weigh In On Cocrystal Pharma

An institutional investor recently bought a new position in Cocrystal Pharma stock. DRW Securities LLC purchased a new stake in Cocrystal Pharma, Inc. (NASDAQ:COCP) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 33,593 shares of the company’s stock, valued at approximately $33,000. DRW Securities LLC owned 0.24% of Cocrystal Pharma as of its most recent SEC filing. Institutional investors and hedge funds own 6.72% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings upgraded Cocrystal Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, June 8th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has an average rating of “Sell”.

About Cocrystal Pharma

Cocrystal Pharma, Inc (NASDAQ:COCP) is a clinical-stage biotechnology company focused on the discovery and development of novel antiviral therapeutics. Utilizing an integrated structure-guided drug design platform, the company combines x-ray crystallography, computational chemistry and medicinal chemistry to identify and optimize small molecule inhibitors targeting key viral enzymes. This approach is intended to accelerate the progression of lead candidates from discovery through preclinical development.

The company’s pipeline includes multiple preclinical programs aimed at treating respiratory and systemic viral infections.